Merrimack Pharmaceuticals sets new terms, now seeking $100 million

By
A A A

Merrimack Pharmaceuticals, which postponed its IPO in February, announced new terms on Monday. The Cambridge, MA-based company now plans to raise $100 million (down from $150 million) by offering 14.3 million shares at a price of $7.00. At the $7 price, Merrimack Pharmaceuticals will command a market value of $647 million (down from $853 million). Merrimack Pharmaceuticals, which uses its Network Biology system to discover and develop cancer treatments, plans to list on the NASDAQ under the symbol MACK. J.P. Morgan is the bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , IPOs

Referenced Stocks: MACK

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Russell’s One Good Reason
Russell’s One Good Reason           
Tammy’s One Good Reason
Tammy’s One Good Reason             
Lisa’s One Good Reason
Lisa’s One Good Reason              
Tammy’s #OneGoodReason
Tammy’s #OneGoodReason              

Stocks

Referenced

Most Active by Volume

61,413,248
  • $7.415 ▲ 23.79%
47,715,652
  • $17.155 ▲ 0.73%
45,640,815
  • $8.935 ▼ 5.15%
29,962,979
  • $74.85 ▲ 1.00%
29,200,513
  • $33.80 ▲ 3.74%
25,756,552
  • $101.2655 ▲ 1.25%
24,210,035
  • $107.66 ▲ 0.64%
23,860,882
  • $2.2499 ▼ 9.64%
As of 10/31/2014, 01:41 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com